-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by alternating clinical remission and relapse periods
.
Over time and inadequate treatment, inflammation can lead to chronic intestinal damage, including the development of fibrous stenosis, abscesses, or fistulas
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by alternating clinical remission and relapse periods
The researchers included patients with Crohn's disease who were treated with infliximab and who had sustained clinical remission without corticosteroids from week 22 to week 54
.
The main observational outcome of the study is whether the patient will undergo major abdominal surgery, CD-related hospitalization, or need to be treated for systemic CD again at the end of the follow-up period
A total of 95 patients were enrolled in this study (mean duration of disease: 4.
5 months), 45 (47%) patients reached the primary endpoint, and the median duration of follow-up conducted by the researchers was 64.
2 months
.
The results of the study showed that there was no significant difference in CD progression-free survival between patients who met or did not meet the primary endpoint at 1, 3, and 5 years (p = 0.
In the cohort of 95 patients with early-stage CD, achieving complete remission under endoscopy and achieving sustained clinical remission with steroids has nothing to do with less disease progression.
The author said that in the cohort of patients with early Crohn’s disease, clinical and endoscopic steroids can be achieved Remission has nothing to do with better disease outcomes
.
Therefore, in the daily practice of managing Crohn's disease patients, more flexible treatment goals should be adopted to improve the prognosis of the disease
In the cohort of 95 patients with early-stage CD, achieving complete remission under endoscopy and achieving sustained clinical remission with steroids has nothing to do with less disease progression.
David Laharie.
Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Leave a message here
